These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 9409357)

  • 1. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.
    Lai EC; Felice KJ; Festoff BW; Gawel MJ; Gelinas DF; Kratz R; Murphy MF; Natter HM; Norris FH; Rudnicki SA
    Neurology; 1997 Dec; 49(6):1621-30. PubMed ID: 9409357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
    Mitchell JD; Wokke JH; Borasio GD
    Cochrane Database Syst Rev; 2007 Oct; (4):CD002064. PubMed ID: 17943766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
    Mitchell JD; Wokke JH; Borasio GD
    Cochrane Database Syst Rev; 2002; (3):CD002064. PubMed ID: 12137643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease.
    Beauverd M; Mitchell JD; Wokke JH; Borasio GD
    Cochrane Database Syst Rev; 2012 Nov; 11():CD002064. PubMed ID: 23152212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.
    Borasio GD; Robberecht W; Leigh PN; Emile J; Guiloff RJ; Jerusalem F; Silani V; Vos PE; Wokke JH; Dobbins T
    Neurology; 1998 Aug; 51(2):583-6. PubMed ID: 9710040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of health-related quality of life in patients with amyotrophic lateral sclerosis in clinical trials of new therapies.
    Damiano AM; Patrick DL; Guzman GI; Gawel MJ; Gelinas DF; Natter HM; Ingalls KK
    Med Care; 1999 Jan; 37(1):15-26. PubMed ID: 10413388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study.
    Boonen S; Rosen C; Bouillon R; Sommer A; McKay M; Rosen D; Adams S; Broos P; Lenaerts J; Raus J; Vanderschueren D; Geusens P
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1593-9. PubMed ID: 11932288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.
    Ackerman SJ; Sullivan EM; Beusterien KM; Natter HM; Gelinas DF; Patrick DL
    Pharmacoeconomics; 1999 Feb; 15(2):179-95. PubMed ID: 10351191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection.
    Lee PD; Pivarnik JM; Bukar JG; Muurahainen N; Berry PS; Skolnik PR; Nerad JL; Kudsk KA; Jackson L; Ellis KJ; Gesundheit N
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2968-75. PubMed ID: 8768860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency.
    Guevara-Aguirre J; Vasconez O; Martinez V; Martinez AL; Rosenbloom AL; Diamond FB; Gargosky SE; Nonoshita L; Rosenfeld RG
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1393-8. PubMed ID: 7536209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
    Meininger V; Drory VE; Leigh PN; Ludolph A; Robberecht W; Silani V
    Amyotroph Lateral Scler; 2009; 10(5-6):378-83. PubMed ID: 19922128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
    Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
    J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure.
    Hirschberg R; Kopple J; Lipsett P; Benjamin E; Minei J; Albertson T; Munger M; Metzler M; Zaloga G; Murray M; Lowry S; Conger J; McKeown W; O'shea M; Baughman R; Wood K; Haupt M; Kaiser R; Simms H; Warnock D; Summer W; Hintz R; Myers B; Haenftling K; Capra W
    Kidney Int; 1999 Jun; 55(6):2423-32. PubMed ID: 10354291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group.
    Lange DJ; Felice KJ; Festoff BW; Gawel MJ; Gelinas DF; Kratz R; Lai EC; Murphy MF; Natter HM; Norris FH; Rudnicki S
    Neurology; 1996 Oct; 47(4 Suppl 2):S93-4; discussion S94-5. PubMed ID: 8858058
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
    Holt RI; Guha N; Böhning W; Bartlett C; Cowan DA; Sönksen PH; Böhning D
    Drug Test Anal; 2017 Jan; 9(1):30-37. PubMed ID: 26888146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group.
    Neurology; 1996 May; 46(5):1244-9. PubMed ID: 8628460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.
    Sorenson EJ; Windbank AJ; Mandrekar JN; Bamlet WR; Appel SH; Armon C; Barkhaus PE; Bosch P; Boylan K; David WS; Feldman E; Glass J; Gutmann L; Katz J; King W; Luciano CA; McCluskey LF; Nash S; Newman DS; Pascuzzi RM; Pioro E; Sams LJ; Scelsa S; Simpson EP; Subramony SH; Tiryaki E; Thornton CA
    Neurology; 2008 Nov; 71(22):1770-5. PubMed ID: 19029516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial.
    Park SB; Vucic S; Cheah BC; Lin CS; Kirby A; Mann KP; Zoing MC; Winhammar J; Kiernan MC
    EBioMedicine; 2015 Dec; 2(12):1916-22. PubMed ID: 26844270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.